Standard Y Balance for Concussion, Brain

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Fort Smith Public Schools, Fort Smith, AR
Concussion, Brain+2 More
Y Balance Plus Visual Perturbations - Device
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

The Y Balance Test for the lower quarter (YBT-LQ) is a movement screen used to assess an athlete's risk for injury. The YBT-LQ is a dynamic balance test where the participant stands on a single leg and with the opposite lower extremity reaches are far in the anterior direction as they can, and this value is measured. The process is repeated in the posterior medial, and the posterior lateral directions. The final values are controlled for leg length of the participants. The YBT-LQ has been shown to be predictive of lower extremity injury in high school basketball players, but it is typically used as part of a battery of tests to determine the athlete's overall injury risk, but more questions remain to be answered. The research question: Is the YBT-LQ predictive of concussion in high school athletes? What are the norms for YBT-LQ in high school athletes? Does history of concussion effect YBT-LQ? Is the YBT-LQ with visual perturbations predictive of concussions? Is the YBT-LQ with visual perturbations predictive of lower extremity injury? What is the impact of visual perturbations on Y-balance and its injury prevention capability? The target student participants will be 9th through 12th grade students; however, 6th to 8th grade students will be allowed to participate depending on the school or organization request. Informed consent will be obtained reiterating that participation is voluntary. Testing utilizing the YBT-LQ will occur, and sport of participation, age, height, weight, dorsiflexion, and leg length will be obtained. Follow up will be made via the athletic trainers and school personnel to indicate the effected athletes. Once the post-test follow up is complete athletes will be able to see their pre-test scores, and any questions will be answered at that time. This will be a longitudinal study where testing will take place at least two times per year, preferably three times per year over 4 years.

Eligible Conditions

  • Concussion, Brain
  • Concussion; Eye

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Report of concussion in past year
Report of lower extremity injury in past year

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Standard Y Balance
1 of 2
Y Balance Plus Stroboscopic Glasses
1 of 2
Active Control

1000 Total Participants · 2 Treatment Groups

Primary Treatment: Standard Y Balance · No Placebo Group · N/A

Standard Y Balance
DiagnosticTest
ActiveComparator Group · 1 Intervention: Y balance · Intervention Types: DiagnosticTest
Y Balance Plus Stroboscopic Glasses
Device
ActiveComparator Group · 1 Intervention: Y Balance Plus Visual Perturbations · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Trial Background

Prof. Alex Habegger, Assistant Professor
Principal Investigator
Arkansas Colleges of Health Education
Closest Location: Fort Smith Public Schools · Fort Smith, AR
N/AFirst Recorded Clinical Trial
1 TrialsResearching Concussion, Brain
0 CompletedClinical Trials

Eligibility Criteria

Age < 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.